Why Life Cycle Integration Is Critical To ADC And XDC Success

By Dr. Campbell Bunce, Chief Scientific Officer, Abzena;, Abzena; and Unmesh Lal, Vice President, Healthcare & Life Sciences, Frost & Sullivan

The antibody drug conjugate (ADC) industry is growing and diversifying, with the market projected to reach $22 billion in 2026 with a compound annual growth rate of 23.3% through 2030. Once niche oncology tools, these modalities have rapidly grown in popularity due to their increased clinical validation, regulatory momentum, and high productivity as oncology treatments. However, to remain competitive and accelerate time to market, developers must prepare for the manufacturing obstacles of ADC development, including bioconjugation complexity, vendor gaps, and linker-payload optimization.

In many cases, costly failures occur during upstream development and CMC, i.e., poorly design bioconjugation chemistry and analytical characterization. Unfortunately, these missteps cannot be corrected in Phase 3, leading to program failures and/or significant approval delays. To ensure a competitive advantage, sponsors must identify risks early and implement strategic approaches to protect late-stage programs. Download the full article to explore proven strategies for effective ADC lifecycle development.